Neal A Patel1, Art Sedrakyan2, Fernando Bianco3, Ruth Etzioni4, Michael A Gorin5, Wei-Chun Hsu2, Jialin Mao2, Paul L Nguyen6, Edward Schaeffer7, Jonathan Shoag1, Andrew Vickers8, Jim C Hu9. 1. Department of Urology, Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY. 2. Department of Healthcare Policy and Research, Weill Cornell Medicine, New York, NY. 3. Nova Southeastern University, Fort Lauderdale, FL. 4. Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA. 5. Department of Urology, Johns Hopkins University School of Medicine, Baltimore, MD. 6. Department of Radiation Oncology, Dana Farber Cancer Institute, Boston, MA. 7. Department of Urology, Feinberg School of Medicine, Northwestern University, Chicago, IL. 8. Department of Epidemiology, Memorial Sloan-Kettering Cancer Center, New York, NY. 9. Department of Urology, Weill Cornell Medicine-New York Presbyterian Hospital, New York, NY. Electronic address: jch9011@med.cornell.edu.
Abstract
INTRODUCTION: We examined the most recent Surveillance, Epidemiology, and End Results release to corroborate temporal trends in nonmetastatic and distant prostate cancer metastases in the United States. METHODS: Surveillance, Epidemiology, and End Results was analyzed for the incidence of nonmetastatic and distant metastasis for men with prostate cancer aged 50-74 and ≥75 years during 2004-2015. Incidence ratios (IR) were calculated relative to the year prior. RESULTS: The incidence of distant metastasis significantly increased from 451.0 to 504.0 per million (IR:1.12, 95% CI:1.01-1.24) from 2011 to 2012 and 532.3 to 586.1 per million (IR:1.10, 95% CI:1.00-1.21) from 2014 to 2015 in men aged ≥75 years. The incidence of distant metastasis did not significantly increase in men aged 55-74 over the study period. CONCLUSION: We demonstrate a sustained and definitive increase in prostate cancer distant metastases in men aged ≥75 years. Although our observational study design cannot pinpoint the exact cause of this increase, which is likely multifactorial, this shift reverses declines in metastases at diagnoses that followed the advent of prostate-specific antigen screening.
INTRODUCTION: We examined the most recent Surveillance, Epidemiology, and End Results release to corroborate temporal trends in nonmetastatic and distant prostate cancer metastases in the United States. METHODS: Surveillance, Epidemiology, and End Results was analyzed for the incidence of nonmetastatic and distant metastasis for men with prostate cancer aged 50-74 and ≥75 years during 2004-2015. Incidence ratios (IR) were calculated relative to the year prior. RESULTS: The incidence of distant metastasis significantly increased from 451.0 to 504.0 per million (IR:1.12, 95% CI:1.01-1.24) from 2011 to 2012 and 532.3 to 586.1 per million (IR:1.10, 95% CI:1.00-1.21) from 2014 to 2015 in men aged ≥75 years. The incidence of distant metastasis did not significantly increase in men aged 55-74 over the study period. CONCLUSION: We demonstrate a sustained and definitive increase in prostate cancer distant metastases in men aged ≥75 years. Although our observational study design cannot pinpoint the exact cause of this increase, which is likely multifactorial, this shift reverses declines in metastases at diagnoses that followed the advent of prostate-specific antigen screening.
Authors: David C Grossman; Susan J Curry; Douglas K Owens; Kirsten Bibbins-Domingo; Aaron B Caughey; Karina W Davidson; Chyke A Doubeni; Mark Ebell; John W Epling; Alex R Kemper; Alex H Krist; Martha Kubik; C Seth Landefeld; Carol M Mangione; Michael Silverstein; Melissa A Simon; Albert L Siu; Chien-Wen Tseng Journal: JAMA Date: 2018-05-08 Impact factor: 56.272
Authors: Tom Budiharto; Steven Joniau; Evelyne Lerut; Laura Van den Bergh; Felix Mottaghy; Christophe M Deroose; Raymond Oyen; Filip Ameye; Kris Bogaerts; Karin Haustermans; Hendrik Van Poppel Journal: Eur Urol Date: 2011-01-18 Impact factor: 20.096
Authors: Laura Van den Bergh; Evelyne Lerut; Karin Haustermans; Christophe M Deroose; Raymond Oyen; Sofie Isebaert; Tom Budiharto; Filip Ameye; Felix M Mottaghy; Kris Bogaerts; Hendrik Van Poppel; Steven Joniau Journal: Urol Oncol Date: 2015-02-02 Impact factor: 3.498